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Abstract
Background: Gastric cancer is the second leading cause of cancer mortality in the world. The receptor tyrosine kinase 
MET is constitutively activated in many gastric cancers and its expression is strictly required for survival of some gastric 
cancer cells. Thus, MET is considered a good candidate for targeted therapeutic intervention in this type of tumor, and 
MET inhibitors recently entered clinical trials. One of the major problems of therapies targeting tyrosine kinases is that 
many tumors are not responsive to treatment or eventually develop resistance to the drugs. Perspective studies are 
thus mandatory to identify the molecular mechanisms that could cause resistance to these therapies.
Results: Our in vitro and in vivo results demonstrate that, in MET-addicted gastric cancer cells, the activation of HER 
(Human Epidermal Receptor) family members induces resistance to MET silencing or inhibition by PHA-665752 (a 
selective kinase inhibitor). We provide molecular evidences highlighting the role of EGFR, HER3, and downstream 
signaling pathways common to MET and HER family in resistance to MET inhibitors. Moreover, we show that an in vitro 
generated gastric cancer cell line resistant to MET-inhibition displays overexpression of HER family members, whose 
activation contributes to maintenance of resistance.
Conclusions: Our findings predict that gastric cancer tumors bearing constitutive activation of HER family members 
are poorly responsive to MET inhibition, even if this receptor is constitutively active. Moreover, the appearance of these 
alterations might also be responsible for the onset of resistance in initially responsive tumors.
Background
Many efforts have been focused in better understanding
the mechanisms of malignant transformation, resulting in
the identification of molecules playing a crucial role in
tumor growth. The race to discover compounds that spe-
cifically inhibit these targets is giving promising results,
and many of these drugs successfully entered clinical tri-
als, opening the era of the "targeted therapies" [1].
Cancer is a multigenic disease arising from the accu-
mulation of different alterations of genes controlling cell
proliferation and/or apoptosis [2]. However, recent stud-
ies in preclinical models demonstrated that tumor cells
may be dependent on a single oncogene for their prolifer-
ation and survival. In fact, the specific inactivation of that
oncogene leads to apoptosis of cancer cells and to tumor
regression. This phenomenon, known as "oncogene
addiction" [3], provides a further rationale for the use of
targeted therapies. However , only a fraction of patients
respond to these therapies, even if the molecular target of
the drug is present in the cell. Moreover, almost invari-
ably, responsive patients develop pharmacological resis-
tance and undergo relapse, often due to the activation of
alternative signaling pathways [4]. One of the major chal-
lenges of targeted therapies is, therefore, to know in
advance which pathways could mediate resistance to the
treatment and to find ways to circumvent these hurdles.
Gastric cancer is the second leading cause of mortality
in the world and the first one in Asia. Despite the
improvement of surgical techniques and the recent avail-
ability of new chemotherapic regimens, the outcome of
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patients with clinical advanced disease is usually poor.
The identification of molecules altered in gastric cancers
has led to the possibility of hitting them by use of specific
targeted drugs. Among them is the receptor for Hepato-
cyte Growth Factor (HGF), encoded by the MET gene,
that promotes a complex biological program called "inva-
sive growth", inducing cells to break intercellular junc-
tions, acquire a motile/invasive phenotype and escape
apoptosis [5]. The improper activation of this program,
due to MET deregulated activation, confers proliferative
and invasive/metastatic ability to cancer cells [6]. Recent
studies demonstrated that MET plays a role in a high per-
centage of human tumors [7]. In gastric cancers this
receptor is frequently constitutively activated; activation
is usually associated with receptor overexpression, that
can be due to gene amplification. Moreover, MET activa-
tion can also result from infection of gastric cells by Heli-
cobacter Pylori, a known predisposing factor for
development of gastric cancer.
We and others have shown that gastric cancer cells
bearing amplification of the MET gene and overexpres-
sion of the receptor, are "addicted" to this oncogene, since
its inhibition results in impairment of tumor growth [8-
10]. On these bases, MET is considered a good target in
gastric cancer.
Recently, molecules targeting MET have gained access
to clinical trials and results are expected soon [11]. Expe-
rience acquired from other RTKs has shown that only a
percentage of patients respond to targeted therapies,
even in the presence of the altered molecular target, and
that almost invariably also responding patients develop
resistance during treatment. Therefore, we were inter-
ested in identifying pathways whose activation could
vicariate the signaling driven by MET. Several studies
have shown the presence of a biochemical and functional
interplay between MET and the HER (Human Epidermal
Receptor) family of RTK (reviewed in [12,13]). This fam-
ily of receptors is frequently altered in gastric cancers
where they are constitutively activated, mainly as conse-
quence of gene amplification. Moreover, in patients with
advanced gastric cancer, co-expression of c-Met and
HER2 has been associated with poorer survival compared
to overexpression of either one [14].
In our work we show that in gastric cancer cell lines
"addicted" to MET, activation of HER family members,
through ligand stimulation or mutational activation, con-
tributes to overcome MET inhibition. This is due to the
partial overlap of downstream signaling pathways com-
mon to MET and HER family. Moreover, we provide evi-
dence that resistance to MET inhibition generated in cell
lines by treatment with high doses of PHA-665752 is
largely due to HER members overexpression.
Results
Ligand-dependent activation of HER family members 
induces resistance to MET inhibition in gastric cancer cells
Cancer cell lines bearing MET gene amplification have
been found to be "addicted" to MET []. GTL16 gastric
cancer cells [15] are the prototype of "MET addicted
cells", containing 11 copies of the MET locus [16], located
on a marker chromosome [17]. The gene is actively tran-
scribed and translated, leading to over-expression of the
MET protein with a constitutive, ligand-independent,
activation [18]. Indeed, when GTL16 cells were cultured
in the presence of a well characterized and specific MET
inhibitor, PHA-665752 (subsequently referred to as PHA)
[19], their viability and growth ability were strongly
impaired (Fig. 1A-1D).
There are several evidences of interplays between MET
and HER family receptors [12,13]; moreover, signaling
networks assembled by oncogenic EGFR and MET show
significant overlapping [20]. We thus stimulated PHA-
treated cells with ligands of the EGF family, to see if they
could activate critical signaling pathways able to rescue
cell viability. As shown in Fig. 1A, 1B, when Epidermal
Growth Factor (EGF) was added to the culture medium,
cells were able to significantly overcome the block of cell
growth induced by PHA. A similar resistance to the effect
of PHA could be induced also by Heregulin-β1 (HRG1-
β1, Fig. 1C, 1D), known to bind HER3 and to induce its
heterodimerization with the other family members [21].
T o formally prove that the observed resistance depends
on the activation of EGFR, upon formation of homodim-
ers or heterodimers with other HER members, the same
experiments were performed in the presence of Gefitinib,
a specific EGFR inhibitor. As shown in Fig. 1A-1D, the
ability of EGF and HRG1-β1 to stimulate cell viability and
growth was lost in the presence of the inhibitor.
F u n c t i o n a l  a s s a y s  e v a l u a t i n g  c e l l  g r o w t h  i n  a d h e r e n t
conditions do not fully recapitulate the biological proper-
ties of tumor cells and, in particular, their ability to sur-
vive and grow in the absence of cell/substrate adhesion.
Therefore, we performed soft-agar assays to evaluate if
EGF and HRG1-β1 could induce resistance to MET inhi-
bition also in conditions of anchorage-independent
growth. As shown in Fig. 2A, 2B, while PHA-treated cells
originated very few colonies in soft agar, the addition of
either EGF or HRG1-β1 recovered their ability to grow in
anchorage-independent manner. Also in this case, resis-
tance to PHA induced by EGF and HRG1-β1 was abro-
gated by Gefitinib (Fig. 2A, 2B).
To verify if the observed behaviour was peculiar to
GTL16 cells or if it was shared by other gastric cancer
cells, bearing MET overexpression due to gene amplifica-
tion (MKN45, SNU5, Hs746T gastric carcinoma cell
lines), we treated them with PHA, in the absence or in theCorso et al. Molecular Cancer 2010, 9:121
http://www.molecular-cancer.com/content/9/1/121
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presence of either EGF or HRG1-β1. The expression of
MET and of the members of the EGFR family in these cell
lines is shown in the Additional file 1. Also in these cell
lines, HRG1-β1 and/or EGF partially recovered cell abil-
ity to grow in the presence of PHA (Additional file 2),
suggesting that HER family activation can interfere with
MET targeting in gastric cancer cells (the poor response
to HRG1-β1 observed in Hs746T cells is paralleled by the
low expression of HER2/HER3 in this cell line (Additional
file 1). The ability of HER family ligands to induce resis-
tance to PHA in soft agar growth was also observed in
MKN45 cells (the only other cell line able to grow in
adhesion-independent conditions) (Additional file 2).
Altogether these findings suggest that the activation of
the HER family receptors confers resistance to PHA-
665752 in gastric cancer cells displaying MET overex-
pression due to gene amplification. Remarkably, the abil-
ity to overcome the effect of MET inhibition is not
common to every growth factor, since neither MSP (Mac-
rophage Stimulating Protein), nor IGF1 (Insulin like
growth factor 1), for which GTL16 cell express the cog-
nate receptors (data not shown), share this property with
EGF family ligands (Additional file.3).
Figure 1 Activation of HER family members rescues PHA-impaired cell viability and growth. (A,C) Viability assays. GTL16 cells were untreated 
(NT) or treated with the PHA (250 nM), in the indicated conditions (EGF 50 ng/ml, HRG1-β1 10 ng/ml, or Gefitinib 250 nM). MET inhibition led to a 
strong decrease in cell viability compared to untreated cells (considered as 100%). Activation of HER members, upon EGF or HRG1-β1stimulation, con-
ferred resistance to MET inhibition (*** P < 0,001). The specificity of the effect is shown by its loss in the presence of Gefitinib. (B,D) Growth curves. 
GTL16 cells were either untreated (NT) or treated with the indicated molecules. The block of cell growth induced by PHA was overcome by EGF or 
HRG1-β1 stimulation (** P < 0,01).
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MET trans-phosphorylation is not essential for the rescue 
by HER family members
I t  i s  w e l l  d o c u m e n t e d  i n  s e v e r a l  e x p e r i m e n t a l  s y s t e m s
that MET and EGFR can interact and trans-phosphory-
late each other (reviewed in [12]). This cross-talk also
exists in GTL16 cells, where EGFR is basally tyrosine-
phosphorylated, as consequence of MET constitutive
activation; inhibition of MET kinase activity, in fact,
results in EGFR dephosphorylation (Fig. 3). As tyrosine
kinase inhibitors do not prevent RTK trans-activation
due to other interacting receptors, we wondered whether
the ability of EGFR to rescue MET inhibition could be
Figure 2 Activation of HER family members rescues PHA-impaired anchorage-independent growth ability. (A,B) GTL16 cells were grown in 
agar for 2 weeks and the amount of viable cells grown in colonies was evaluated with the Alamar Blue dye. MET inhibition with PHA (250 nM) resulted 
in impairment of cell ability to grow in an anchorage-independent manner compared to untreated cells, considered as 100%. Stimulation with EGF 
(50 ng/ml), or HRG1-β1 (10 ng/ml), rescued the ability of PHA-treated cells to form colonies (*P < 0,05; *** P < 0,001).
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Figure 3 Activation of AKT and MAPK pathways is required for resistance to MET blocking. A) WB analysis of total GTL16 lysates. PHA treatment 
or MET silencing (DOXY) resulted in strong impairment of MET, EGFR, HER3, AKT and p42/44 MAPK phosphorylation. In these conditions, stimulation 
with EGF (5 ng/ml) or HRG1-β1 (10 ng/ml) restored AKT and MAPK activation. B) Cell viability assay in PHA-inhibited or not GTL16 cells. The presence 
of AKT and MAPK inhibitors abrogated the resistance to MET inactivation obtained with the two ligands (*** P < 0,001), while each inhibitor alone has 
only a partial effect.. C) WB analysis to control the effectiveness of LY294002 and U0126.
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due to trans-phosphorylation of the tyrosines located in
the MET tail, acting as docking sites for most signal
transducers [22]. To investigate this point, we took
advantage of a RNA interference system able to silence
MET in an inducible manner [10]. Upon doxycycline-
induced MET silencing (Fig. 4C), GTL16 cells were
strongly inhibited in their viability and in their anchor-
age-dependent and independent growth ability (Fig. 4A,
4B). However, in all the biological assays performed, the
treatment with EGF or HRG1-β1 could overcome the
effect of MET silencing (Fig. 4A, 4B), similarly to what
seen with PHA. Since the silencing of MET was not com-
plete, we cannot completely rule out the possibility that
transphosphorylation may play a role in resistance. How-
ever, similar results obtained by chemical inhibition and
by silencing suggest that the ability to overcome resis-
tance is probably not due to MET trans-phosphorylation
by EGFR, but, very likely, to the activation of MET-inde-
pendent and parallel pathway(s).
To understand which biochemical events, downstream
HER family, are responsible for the observed resistance to
MET blocking, we analyzed the levels of AKT and MAPK
Figure 4 MET trans-phosphorylation is not essential for the rescue exerted by HER family members. A) Cell viability assay (left) and growth 
curve (right). GTL16 cells transduced with a doxycycline-inducible shRNA system were treated (DOXY) or not (NT) with doxycycline (1 μg/ml) to silence 
MET, and stimulated or not with EGF (50 ng/ml) or HRG1-β1 (10 ng/ml). Activation of HER members partially rescued inhibition of cell viability and 
growth induced by MET silencing (** P < 0,01). B) Cells were grown in agar and the number of viable cells was quantified with the Alamar Blue dye. 
Stimulation with EGF or HRG1-β1 partially rescued anchorage-independent growth ability in MET-silenced cells (DOXY; *** P < 0,001). (C) WB analysis 
showing effectiveness of MET silencing, 48 hours upon addition of doxycycline.
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activation in GTL16 cells (untreated, treated with PHA or
silenced for MET expression), not stimulated or stimu-
lated with EGF or HRG1-β1. As shown in Fig. 3A, a
remarkable AKT and MAPK activation was observed
after stimulation with EGF or HRG1-β1, upon MET inhi-
bition or silencing. Notably, AKT activation was stronger
when induced by HRG1-β1 compared to EGF stimula-
tion. Phosphorylation of both AKT and MAPK was abro-
gated in the presence of Gefitinib, demonstrating its
dependency on EGFR activation (data not shown).
To evaluate the role of the HER-dependent AKT and
MAPK activation in conferring resistance to MET inhibi-
tion/silencing, we performed viability assays in the pres-
ence of specific AKT and MAPK inhibitors (LY294002
and U0126, respectively), whose activity was tested by
Western blot (Fig. 3C). As shown, the presence of both
inhibitors abrogated the ability of EGF and HRG1-β1 to
overcome MET targeting (Fig. 3B), while each single
inhibitor had only a partial effect. These data suggest that
activation of AKT and MAPK pathways is required for
resistance to MET blocking.
Constitutive activation of HER family members prevent the 
in vitro and in vivo effectiveness of MET inhibition
The most common EGFR activating alterations in human
tumors are receptor point mutations (such as the L858R
mutation, [23]) and the onset of TGFα autocrine produc-
tion [24,25]. We thus investigated if the presence of these
pathological alterations could induce resistance to MET
inhibition in GTL16 cells. Through lentiviral transduc-
tion, we obtained GTL16 cells - already bearing the
inducible shRNA system against MET [10] - stably
expressing either the constitutively active EGFR-L858R
(Fig. 5A, top panel) or TGFα (Fig. 5B, top panel). Cells
transduced with an empty vector were generated as con-
trol. The transduced cells were tested for their ability to
grow when MET was silenced or kinase-inhibited. As
shown in Fig. 5A, cell expressing the EGFR-L858R
mutant were able to partially overcome the effect of MET
silencing/inhibition in all the assays. In cells growing in
anchorage-independent conditions, the ability to induce
resistance to MET blocking was further increased by the
stimulation of mutant EGFR with physiological concen-
trations of EGF (a situation closely resembling a possible
in vivo scenario). As expected, the effect of EGFR-L858R
was abolished by Gefitinib (data not shown).
Similar results were obtained when GTL16 cells were
transduced with the TGFα cDNA. As shown in Fig. 5B,
also the autocrine-mediated activation of EGFR impaired
PHA/shRNA effects on cell growth and colony forma-
tion. This suggests that constitutive activation of HER
members, frequent in human tumors, can contribute to
resistance to MET targeted therapies.
In order to verify the in vivo relevance of our findings,
we performed xenograft experiments in mice. GTL16
cells expressing the inducible shRNA system to silence
MET and then transduced either with an empty vector, or
the EGFR-L858R mutant, or TGFα, were subcutaneously
injected in nude mice. After one week, half of the mice of
each experimental group (Mock, EGFR-L858R and
TGFα) received doxycycline to silence MET in the tumor.
As shown in Fig. 5C, MET silencing strongly delayed
tumor onset in mice injected with control cells. In fact,
after 40 days of MET silencing, the incidence of visible
tumors was only 20%. However, tumors expressing
EGFR-L858R or having the TGFα autocrine production
were considerably resistant to MET silencing, as demon-
strated by a complete rescue in tumor incidence (Fig. 5C).
The expression of EGFR -L858R or TGFα does not signif-
icantly promote tumor growth in untreated cells
(expressing MET). These data demonstrate that activat-
ing mutations of EGFR and TGFα autocrine loop can
impair the effect of MET silencing in vivo.
HER family members contribute to the onset of secondary 
resistance to MET inhibition
To verify if HER members are involved in secondary
resistance to MET inhibition, we continuously treated
GTL16 cells with a dose of 500 nM PHA, mimicking a
hypothetical clinical treatment regimen. After few
months of PHA administration, cells developed resis-
tance to the drug. In fact, while GTL16 parental cells
treated with 500 nM PHA displayed an almost complete
abrogation of growth, the resistant cells were only slightly
a ff ect ed by PHA ( a bout  10%  of  c e l l via bi lit y r edu ct ion
compared to untreated parental cells) (Fig. 6A). The anal-
ysis of these cells revealed that the MET gene was neither
mutated nor amplified, and that other master regulators
of cell proliferation, such as H-RAS and K-RAS, B-Raf and
PI3KCA  had none of the known mutations (data not
shown). We then analyzed the HER family status, finding
that the resistant cells showed a significant increase in the
expression level of these receptors (especially HER2 and
HER3), compared to parental cells (Fig. 6B). No muta-
tions neither gene amplification were present in EGFR
(exons 18, 19, 21, data not shown). In order to verify if the
overexpression of HER2 and HER3 could be responsible,
at least partially, for the development of resistance, we
silenced both receptors in parental and in resistant cells
(Additional file 4) and tested the viability of these cells in
the absence or presence of PHA. Interestingly, we
observed that HER2/HER3 silencing significantly
reduced the ability of resistant cells to grow in the pres-
ence of PHA (Fig. 6C), with no significant effect on the
parental counterpart.
Collectively, these findings demonstrate that alterations
in HER family members can actually contribute to theCorso et al. Molecular Cancer 2010, 9:121
http://www.molecular-cancer.com/content/9/1/121
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Figure 5 Mutated EGFR or TGFα autocrine production impair the biological effects of MET targeting. A-B) Cells, bearing the doxycycline-in-
ducible MET shRNAs, were transduced with the mutated form of EGFR (L858R) (A) or with the Hys-tagged TGFα (B). Top, WB showing the expression 
of transduced molecules, compared to cells transduced with the empty vector; Upper graph, growth curves of GTL16, GTL16-L858R (A) or GTL16-TGFα 
(B). The effect of MET silencing (DOXY) or inhibition (PHA) was compared with untreated cells. After six days, only cells bearing EGFR-L858R or TGFα 
were able to grow when MET was inactivated (A ** P < 0,01; B *** P < 0,001). Lower graph, anchorage-independent growth assays. Cells having an 
activated EGFR (GTL16-L858R, A or GTL16-TGFα, B) formed colonies in soft-agar in the absence of MET signaling, while wt cells did not (A-B ** P < 0,01). 
Stimulation of GTL16-L858R cells with a physiological concentration of EGF (1 ng/ml) resulted in further increase of anchorage-independent growth, 
only in the absence of MET signaling. C) The cells used for biological assays were injected subcutaneously in CD1 nude mice. MET silencing was main-
tained in vivo by adding doxycycline (1 mg/ml) to mice drinking water. The graph shows the Kaplan-Meier-like analysis of tumor latency. After 40 days, 
70% of mice injected with GTL16 cells and treated with doxycycline were tumor-free. On the contrary, only 30% of mice injected with GTL16-L858R 
and GTL16-TGFα were tumor-free, despite MET silencing. EGFR-L858R and TGFα had no significative effect in promoting tumor growth in untreated 
GTL16.
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onset of secondary resistance to PHA in initially respon-
sive tumor cells.
Discussion
The clinical experience derived from use of drugs target-
ing molecules that play critical roles in human tumors has
shown that their efficacy critically depends on the pres-
ence of the altered target in the neoplasm [26]. However,
even in these conditions, a response to the inhibitor is
seen only in a fraction of patients (primary resistance)
[27]. Moreover, even in responding patients in which the
drugs are initially successful in impairing tumor growth,
their efficacy decreases or is abrogated in a short time
period, due to appearance of "secondary resistance" [4].
Most commonly, primary resistance is due either to con-
stitutive activation of pathways downstream to the tar-
geted molecule or to the engagement of alternative or
redundant parallel signaling pathways that vicariate the
lack of signal due to target inhibition. Secondary resis-
tance can be due either to the same mechanisms, or to
genetic alterations of the target, such as gene amplifica-
tions (rendering the amount of available drug not suffi-
Figure 6 HER family members contribute to onset of resistance to PHA treatment. (A) Cell viability of GTL16 cells resistant to 500 nM PHA (GTL16 
R500) compared to wt cells, grown in the presence of the drug for 96 hours. Growth of GTL16 R500 was not affected by the PHA. (B) Expression levels 
of HER family members in GTL16 cells wt or resistant to PHA, evaluated by Real time PCR. Absolute values were normalized to GAPDH. (C) Cell viability 
upon silencing of HER2/HER3. In GTL16 cells expression of HER2 and HER3 was silenced. While the silencing of the two receptors did not affect viability 
of wt cells, in GTL16 R500 the absence of HER2 and HER3 resulted in increased sensibility to PHA (*** P < 0,001).
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cient to block the target) or the appearance of point
mutations (that prevent the interaction between the tar-
get and the drug). The recent availability of drugs that
simultaneously inhibit multiple targets or the possibility
to perform association therapies able to block synergistic
signal transduction pathways has underlined the impor-
tance of identifying these functional and biochemical
interactions, potentially involved in the appearance of
resistance to targeted drugs.
Gastric cancer is an aggressive cancer, constituting a
major cause of cancer-related deaths worldwide. Even if
traditional therapies such as surgery, chemotherapy and
radiotherapy have improved in recent years, patients with
advanced disease have a poor prognosis, with a 5-year
survival of less than 30%. For this reason, there is an abso-
lute need for the integration in the treatment of this can-
cer of new drugs, targeting the genetic lesions present in
the tumor. Molecular analyses performed in gastric can-
cer samples have shown that among the genes frequently
altered in this tumor are tyrosine kinase receptors of the
MET and HER families. The MET gene has been shown
to be amplified in human gastric cancers and gastric can-
cer cell lines; amplification is known to be responsible for
receptor overexpression and ligand-independent consti-
tutive activation. Activating mutations have also been
identified in some tumors of this histotype [6]. The role of
the MET gene in human tumors has been firmly estab-
lished [11] and it has also been demonstrated that genetic
alterations of MET can be selected for the long-term per-
sistence of the transformed phenotype as gene amplifica-
tion is more frequent in metastatic lesions rather than in
primary tumors [28]. Moreover, "in vitro" and preclinical
models have shown that tumor gastric cells displaying
MET gene amplification are "addicted" to the constitutive
activity of this receptor for their growth and maintenance
[8-10], thus suggesting that patients affected by this can-
cer could be ideal candidates for anti-MET targeted ther-
apies. Indeed, clinical trials evaluating the effect of MET
inhibition in these patients are ongoing [11]. It is also very
puzzling to note that Helicobacter Pylori, a well known
risk factor for this neoplasm, requires MET activation to
exert its pro-tumorigenic effects [29]. Several reports
have also identified in gastric cancers quantitative and
qualitative alterations of members of the HER family, the
most frequent being gene overexpression and amplifica-
tion, even if also activating mutations have been detected
[30,31]. Clinical trials targeting HER family members are
thus ongoing in patients affected by gastric cancers [32].
It is important to note that in patients with advanced gas-
tric cancer, co-expression of c-MET and HER2 has been
associated with poorer survival compared to overexpres-
sion of either one[14]. These data thus suggest that, in
some cases, co-targeting of both these molecules could
be of clinical importance.
Several experimental evidences suggest the existence of
biochemical and functional interplays between the mem-
bers of the HER family and MET. Moreover, recent stud-
ies have shown that resistance to Gefitinib can be due to
MET amplification [33]. In this case, MET overexpression
and constitutive activation leads to HER3 trans-phospho-
rylation and activation of HER3-dependent survival path-
ways. In these cells, co-inhibition of MET and EGFR
reverted resistance to Gefitinib. Since MET plays a role in
mediating resistance to EGFR inhibition, we wondered if
also the reversal was true. Some works have shown that,
in vitro, activation of HER family members can lead to
MET phosphorylation, but the role of this interplay has
never been evaluated in vivo and in the contest of cells
resistant to MET inhibitors [34,35].
As works conducted on other RTKs highlighted the
ability of laboratory models to identify clinically relevant
mechanisms of drug resistance, the aim of our work was
to try to evaluate, in vitro and in preclinical models, the
possible role of HER family receptors in mediating pri-
mary resistance to MET inhibition.
We took advantage of gastric MET-addicted tumor cell
lines that stop proliferating upon treatment with specific
MET inhibitors. We found that activation of HER family
members in MET addicted cells, after MET inactivation,
is able to increase cell viability in vitro, and to recover
tumorigenicity in vivo. This observation is important if
translated into a clinical context. In fact, gastric tumors
that display MET gene amplification (10% of cases) are
potentially addicted to MET expression and can be con-
sidered ideal targets for anti-MET therapies; however,
aberrant activation of HER family members has also been
shown to be concomitant in these tumors [36,37]. This
means that the effect of MET inhibition could potentially
be neutralized or attenuated by the parallel activation of
receptors of the HER family. This implies that combinato-
rial inhibition of both MET and HER could likely improve
the therapeutic effect. It is critical to underline that not
all the growth factor-activated pathways can compensate
for the lack of signal due to MET inhibition, as shown by
d a t a  r e p o r t e d  i n  t h i s  p a p e r .  D i f f e r e n t l y  f r o m  p r e v i o u s
observations in HER-addicted cells, the biological effects
due to HER members activation was not due to their abil-
ity to trans-phosphorylate MET. In fact, the resistance
was present not only in cells in which MET was inhibited
by the specific small molecule, but also in cells in which
the receptor was no longer present - and thus not avail-
able for trans-phosphorylation - due to shRNA-mediated
silencing. These results suggest that the resistance
induced by HER members activation may be rather due
to their ability to activate signaling pathways that are crit-
ically overlapping with those generated by MET, such as
activation of the AKT/MAPK pathways [20].Corso et al. Molecular Cancer 2010, 9:121
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Finally, we have generated gastric cells resistant to a
MET specific inhibitor and, upon ruling out the presence
of MET gene amplification or mutations in either MET
itself or other downstream signalling molecules such as
RAS, Raf or PI3K (all of them being implicated in the
acquisition of resistance to treatment with small mole-
cules inhibitors), we found that the levels of HER2 and
HER3 were significantly increased in these resistant cells.
Moreover, HER3 silencing led to reversion of the resis-
tance to MET inhibitors and to decreased cell viability.
These data suggest that a molecular mechanism exploited
by addicted cells to overcome the pro-apoptotic effect of
MET inhibition may be the increased expression of HER
family members, enhancing the sensibility to their cog-
nate growth factors, which are usually available in the
tumour microenvironment.
Conclusions
In our work we studied the molecular mechanisms that
could cause resistance to therapies targeting MET in gas-
tric cancer. Altogether our data suggest that even in the
cellular contexts that are more likely to respond to treat-
ment with MET inhibitors, activation of HER family
receptors -which is rather frequent in gastric tumors- can
impair the biological response to treatment and can con-
cur to the appearance of resistance. This should be taken
in consideration in light of using new drugs or new asso-
ciation schemes that could concomitantly inhibit both
these receptors and act synergistically.
Methods
Cell culture and compounds
SNU-5, NCI-H1993 cell lines were from ATCC, EBC-1
from JCRB. GTL16 cells were described in [15]. EGF was
from Sigma (Milan, Italy), HRG1-β1 and IGF-1 from
R&D; MSP was produced as in [38]. LY294002 was from
Calbiochem, U0126 from Promega, PHA-665752 from
Tocris Bioscience, Gefitinib from Sequoia Research Prod-
uct. The EGFR L858R vector was kindly provided by Dr.
Yarden [39]. TGFα was cloned in p156RRLsin.PPTh-
CMV.MCS.pre [40]. The MET-shRNA was described in
[10], the HER2-shRNA in [41]; the HER3-siRNA was
from Sigma (MISSION siRNA, SASI_Hs01_00196190).
Virus preparation, cell transduction and electoporation
Lentiviruses were produced as in [42]. Cells were trans-
duced using 40 ng/ml of p24. Electroporation was per-
formed with siRNAs 2 nM using the Cell line
Nucleofector Kit V and Nucleofector II machine (Amaxa
biosystems).
Western blot analysis
Cells were starved in serum-free medium for 24 hours
and then treated with EGF (5 ng/ml) or HRG1-β1 (10 ng/
ml) for 10 minutes. Cells were lysed in LB buffer (2% SDS,
0.5 mol/L Tris-HCl (pH 6.8)). Primary antibodies: anti-
phospho-Tyrosine (G10) (Upstate Biotechnology); anti-
Actin (1-9), anti-HER3 (C-17) and anti-HER2 (C-18)
(Santa Cruz Biotechnology); anti-vinculin (Sigma, Milan,
Italy); anti-MET DL21 [43]; anti-phospho-MET Tyr1234/
1235 (Cell Signaling Technology); anti-AKT, anti-phos-
pho-AKT (Ser473), anti-p42/44 MAPK and anti-phos-
pho-p42/44 MAPK Thr202/Thr204 (Cell Signalling
Technology). Secondary antibodies were from Amer-
sham. Detection was performed with ECL system (Amer-
sham).
Biological assays
Growth curves experiments were performed as in [25];
viability was evaluated on day.4, as in [44]. Growth in soft
agar was performed as in [45], and was quantified with
the Alamar Blue indicator dye (Trek Diagnostic Systems).
Measurements were recorded using a DTX 880-Multi-
mode plate reader (Beckman-Coulter).
Real-Time PCR analysis
Total RNAs were extracted using TriReagent lysis buffer
(Applied Biosystem). 2 μg of total RNA were retro-tran-
scribed using random primers; cDNA was subjected to
quantitative PCR, using Sybr green Master MIX (Applied
Biosystem). Real-time PCR was performed with an ABI
PRISM 7900HT (Applied Biosystems, Milan, Italy).
Primer sequences are available from the authors.
Xenograft transplantation experiments
3 × 105 tumor cells were injected subcutaneously in 6-
week-old immunodeficient nu-/- female mice on a Swiss
CD-1 background (Charles River Laboratories, Lecco,
Italy). Tumor appearance was considered when tumor
volume (calculated as in [46]) reached 100 mm3 and mon-
itored for 40 days. Animal procedures were approved by
the Ethical Commission of the University of Turin and by
the Italian Ministry of Health.
Generation of cancer cell lines resistant to MET inhibitor
GTL16 cells were continuously cultured in the presence
of a fix dose of PHA-665752 (500 nM), changing the
media every 3 days. Resistance to MET inhibitor
appeared in 6 months, after which cells were analyzed as
described.
Statistics
Results are means of at least three different independent
experiments + standard error mean (s.e.m.) or standard
deviation. Comparisons were made using the two-tailed
Student's t-test.Corso et al. Molecular Cancer 2010, 9:121
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